Pharmacology of fibrates;Farmacologia do fibratos

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue SUPPL. 5, 2005, Pages 15-16

  Xavier, Hermes Toros ^a  

^a UNILUS   (Brazil)

Author keywords

Fibrates; Lipid metabolism; Pharmacology

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CYTOCHROME P450; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ARTICLE; DRUG ABSORPTION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER METABOLISM; PHARMACOLOGICAL PARAMETERS; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION;

ANTICHOLESTEREMIC AGENTS; CLOFIBRATE; HUMANS; LIPID METABOLISM;

EID: 31144465577     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1186/1745-0179-1-15     Document Type: Article

References (9)

1. Santos RD et al. III Diretrizes brasileiras sobre dislipidemias e diretriz de prevenção da aterosclerose do departamento de aterosclerose da sociedade brasileira de cardiologia. Arq Bras Cardiol. 2001;77(supl III):1-48.
2. Frick MH et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
3. Rubins HB, Robins SJ. Conclusions from the VA-HIT study. Am J Cardiol.2000; 86:543-4.
4. Treatment Effects on Serum Lipoprotein Lipids, Apolipoproteins and Low Density Lipoprotein Particle Size and Relationships of Lipoprotein Variables to Progression of Coronary Artery Disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648-56.
5. Frick MH et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997 ;96:2137-43.
6. Vakkilainen J et al.; DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003 ;107:1733-7.
7. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives. Atherosclerosis 2003;171:1-13.
8. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53:409-35.
9. Martinez LRC, Santos RD. Papel dos fibratos no tratamento das dislipidemias In: Xavier HT(ed.) Manual de dislipidemias e cardiometabolismo. São Paulo: BBS Editora, 2004. p.157-165.